Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rob Sargent how are you managing this shell when you are managing APHD?
How many other shell companies do you own?
This is nonsense, turn yourself in already?
IMO
Do not allow this fraud to continue CEO's cannot continue to run multiple companies into the ground while diluting billions of shares for personal wealth?
IMO
Mr. Sargent can you address the manipulation in your other shell APHD?
I see you might be waking up this other con job SNBP with some trading today but can you comment of the theft that is taking place on some of your other companies?
Please Bob, you can't just continue to make up companies obtain shells then dilute them?
You could go to jail eventually if fraud is committed?
Hello Bob are you here?
We are?
IMO
SNBP filed form 15, talk of possible merger and shareholders would be bought-out.
http://www.dailyfinance.com/rtn/pr/sinobiopharma-filed-a-form-15/rfid479477265/?channel=pf&source=esadlfhlnal0001&lidx=2
What I don't see, is any indications the company is floundering.
Often before a major break-through, companys are quiet with few PR's.
I can understand PPL becoming impatient, so little movement in such a long period of time.
Some retail bailing out at bargan-prices. When the small-fry get taken, the ask remains @ .35
Yawn!!!....tracking this stock is like watching paint dry.
A tiny 8K filing, about resignation of independant director.
March 24th, 2011..8K,
http://ih.advfn.com/p.php?pid=nmona&article=47010574
I obviously need to start paying attention to this stock again. Been holding a constant plug of shares for more than a year now waiting for some shift to start.
Edging up slowly under low volume is not a bad sign.
Agreed. Good to see the share price above (marginally) my cost average for once.
Might have to see about adding some shares next week. Have to decide whether to put the bucks here, or one I hold.
Have a good weekend all.
Just above .295 has been resistance for quite a while. Any close above that is good, open higher I hope next week.
GLTA.
I would just like to see it edge up above my cost average of ~$0.31 and hold that for a while.
That - would be at least a good start.
Anybody want to sell some to keep it moving?...at .30 or above..
Whoever sold some at .26's is kicking themselves, I'd bet...
Not alot going on, I admit....but someone did buy at .31 today.
And larger at .30
Any buys above the .29's fine by me.
Nobody ever posts here, so nothing to read. I think we're all just patiently waiting for the next earnings report.
YAWN!!!
Apparently - has been kind of quiet in here of late. Howdy all,.... assuming anybody is reading this board any more.
Agreed - it looked like a one-tme, if siginficant, expense.
Will bear watching over the next quarter or two though. The rest of the numbers looked fairly good to me.
I'll go back and reread it again against the last couple of reports and see if anything pops up on a second reading.
Not pretty by any means but it was mainly a one time event. There was additional expenses for a sales office in Beijing which should be kept an eye on.
I should have a read through it again.
rich
10Q released Jan 19th. It doesn't look pretty...
What was the report? Link? Was there something in the 10Q or 10K I should take a look at?
Harbinger research continues in it's "Buy" reccomendation.
http://harbingerresearch.ir.stockpr.com/sinobiopharma
I bailed as well right after I saw the report. Not sticking around for the slow fall...
Good luck to those that stay & sorry for the downdraft as I exit my position.
The report didn't make me want to camp here any longer.
regards,pappy
Thanks for the heads up pappy on SNBP you put out on our little board. I'm liking the prospects for the future here.
malc
Yup, I was aware they are coming. I think profits will show a decent rise, but I would be suprized if they were Stellar, that comes a bit later in this years earnings.
It will be interesting to see what percentage of their profit has come from the sales by partners, Via the licencing agreements.
GLTY.
Remember earnings are due Jan. 15th.
Hope this buying means positive news.
.30 back, did wake up a bit. Lets keep going.
Been along time since the last 30's.
New Year 1st post...someone kick snbp and wake it up!
Lets see this company start to roll...
Nice to see the buying continue again today.
Buy volume swamped sell at the bid volume almost 3-1.
With 6=50k trades done at the ask or between the bid & ask.
I have seen no news to account for this increased volume other than the new company presentations available on snbp's website.
I was asked on Yahoo where I might sell shares since the pps is increasing.
Well I believe the present fundamentals support a pps around $0.40 or 8x 2011 eps.
However snbp is a long term position for me based on the CEO's experience & ability to deliver expected results.
So I plan to trade around a core position as long as the bottomline continues to outpace the increased share count by at least 20%.
Let's see how & when they bring more new drugs on line as there is no doubt that the pipeline is very promising.
As more new drugs make a dent in overall revenue I would consider raising my fair value p/e but until then I feel a forward p/e ratio around 8 considering this is a Chinese pharm. is about right.imo
YW, and thanks back.
Thank you.
And may you & yours enjoy the time together.
It's an odd stock. It's not the first time it's done well on a bad day.
rich
In the 1st hour of trading today blocks of 46-30-35-50k went thru at the ask.
Thanks for that article.
Bloomberg Interview: Lequn Lee Huang
http://www.bloomberg.com/news/2010-11-12/specialty-drugmaker-sinobiopharma-takes-on-big-pharma-in-china.html
rich
I also like that eps were up in spite a four fold increase in R&D.
However some were disappointed that new products didn't contribute to revenue on a percentage basis.
The flagship product should continue its strong revenue growth with improving margins for a few more years so earnings should show solid gains regardless.
However as long as snbp is seen as a one product company with a large increase in shares outstanding the stock will probably underperform.
New products are not suppose to make a big contribution until next year but I would like to see revenue progress from newer products this year.
As a percentage of total revenue the flagship product is contributing a bigger share of total revenue because of its continued strong growth so when revenue from other products contribute enough to stop this trend I see SNBP deserving a higher p/e ratio since growth from their pipeline of new products can substain good longterm growth of 30%+ for many years after their original producer of revenue see's its growth slowing down.
10 Q out....gains in cash and assets.
http://www.dailyfinance.com/company/sinobiopharma-inc/snbp/nab/10-Q/101125183/html/sec-filings
1st qtr number should be any time now for the qtr that ended Aug 31.
I think we were talking about EPS not dividends.
Chinese companies have found ways of paying dividends - SIAF for instance. In the end PRC wants to stop currency converting into Yuan. I think they would be happy to see people moving out of Yuan. Anyway, as you say a young growing company isn't worrying about dividends at this time.
rich
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
400
|
Created
|
09/26/08
|
Type
|
Free
|
Moderators |
117,587,608 as of 01/20/2011 (By Quotemedia) ......an increase of 17.6 million(Approx) from split for compensation for itellectual-propertys and services.
After a distinguished 20-year medical career in the U.S. that saw him become the Principal Scientist at Bayer's Pharmaceutical Division Research Centre in New Haven, CT, Dr. Lequn Huang returned to his native China to become founding Chair of Dong Ying Pharmaceutical Co. Ltd. in 2004.
He proceeded to recruit R&D and management teams to accelerate the growth of Dong Ying into a premier developer and manufacturer of innovative pharmaceuticals for the Chinese domestic and international markets.
Headquarters and a 30,000 sq. meter SFDA GMP-certified production facilities are located in the Nantong Economic and Technology Development Zone, which qualifies Sinobiopharma for extensive tax benefits. R&D labs are located in Nanjing, a major R&D centre with several universities and research institutes. A nationwide distribution network enables Sinobiopharma to market its products in every major city in China.
Dr. Lee Huang, "The market has shown a strong need for our flagship product, KuTai-(cisatracurium b.)
and the sales increases from this product are expected to continue for the next 2 years."
These upgrade were done to facilitate the expected increases in orders, and to provide economies of
scale. Production of cisatracurium besylate at the Dongying facility was uninterupted.
Current output could be doubled at anytime without the need for additional expenditures for new equiptment.
Financial highlights include:
2010 fiscal year
Sales revenue increased to $1,902,376 for the six months ended November 30, 2008 from $583,748 in the corresponding period in 2007.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |